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Abstract
Objectives To determine the population level costs, effects, and cost
effectiveness of selected, individual based interventions to combat
chronic obstructive pulmonary disease (COPD) and asthma in the context
of low and middle income countries.
Design Sectoral cost effectiveness analysis using a lifetime population
model.
Setting Two World Health Organization sub-regions of the world:
countries in sub-Saharan Africa with very high adult and high child
mortality (AfrE); and countries in South East Asia with high adult and
high child mortality (SearD).
Data sources Disease rates and profiles were taken from the WHO
Global Burden of Disease study; estimates of intervention effects and
resource needs were drawn from clinical trials, observational studies,
and treatment guidelines. Unit costs were taken from a WHO price
database.
Main outcome measures Cost per disability adjusted life year (DALY)
averted, expressed in international dollars ($Int) for the year 2005.
Results In both regions low dose inhaled corticosteroids for mild
persistent asthma was considered the most cost effective intervention,
with average cost per DALY averted about $Int2500. The next best value
strategies were influenza vaccine for COPD in Sear-D (incremental cost
$Int4950 per DALY averted) and low dose inhaled corticosteroids plus
long acting β agonists for moderate persistent asthma in Afr-E
(incremental cost $Int9112 per DALY averted).
Conclusions COPD is irreversible and progressive, and current
treatment options produce relatively little gains relative to the cost. The
treatment options available for asthma, however, generally decrease
chronic respiratory disease burden at a relatively low cost.
Introduction
Chronic respiratory diseases represent a major disease burden,
with chronic obstructive respiratory disease (COPD) and asthma
estimated to affect 64million and 235million people worldwide,
respectively.1 In the latest estimates, COPD was the fourth
leading cause of death in 2004, causing around three million
deaths or 5.1% of all deaths in the world, and in 2030 it is
projected to become the third leading cause, with 5.8 million
or 8.6% of total deaths.1Asthmamorbidity andmortality account
for around 1% of all disability adjusted life years (DALYs),
equivalent to 16 million DALYs lost per year worldwide.1
Much of the projected increase in COPD prevalence and
mortality is closely associated with increases in tobacco smoking
and exposure to indoor smoke from solid fuel for cooking and
heating, as well as changing demographics in many countries.2-4
For asthma, the two main environmental risk factors are
allergens and viral infections. Environmental risk factors
associated with COPD are likely to disproportionately affect
low andmiddle income countries, especially in Africa and Asia,
which currently account for almost 90% of COPD deaths
worldwide.5-8According to the Global Burden of Disease study,9
the East Asia and Pacific region, primarily China, is the most
affected in global terms, with 50% of the global annual mortality
from COPD occurring there. The projected increase in the
world’s urban population from 45% to 59% by 202510will likely
lead to increased prevalence of chronic respiratory diseases
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worldwide, since urbanisation and adoption ofWestern lifestyle
are major explanatory factors for increased asthma rates.
A number of treatments are available for both conditions that
can help control the symptoms and slow disease progression.
Current information on the cost effectiveness of interventions,
however, is limited to randomised trials results conducted in
developed countries. No information is available on the health
effects and costs of interventions at a population level in
developing regions of the world. Accordingly, the aim of this
paper is to provide evidence on themost cost effective individual
based interventions for COPD and asthma management in
developing regions. Population based preventive interventions,
which include tobacco control policies and strategies to improve
indoor air quality in households, are covered in other disease
models (for smoking and indoor air, respectively).11 12
Methods
TheWHO-CHOICEmodelling framework13 14was used to carry
out a generalised cost effectiveness analysis using estimates of
total costs and effects of asthma and COPD interventions (see
general appendix on bmj.com). This paper reports the results
for two WHO epidemiological sub-regions, one in Africa
(countries with high child and very high adult mortality,
henceforth denoted “AfrE”), and the other in South East Asia
(countries with high child and adult mortality, henceforth
denoted “SearD”).
Characterisation of interventions
Interventions included in this analysis were those directed at
the treatment of established disease (see appendix on bmj.com
for details).
Chronic obstructive pulmonary disease (COPD)
According to the spirometric classification of severity adopted
by the Global Initiative for Chronic Obstructive Lung Disease
(GOLD),15 COPD is characterised by airflow limitation, with a
ratio of lung function levels of forced expiratory volume in one
second (FEV1) to forced vital capacity (FVC) <70% and a
post-bronchodilator FEV1 of <80% of the predicted value.
Additional symptoms such as cough, sputum production,
shortness of breath, and fatigue can be observed but are not
always present, especially in the initial stages of the disease.
For determining the impact of treating people with COPD at
various stages of progression, we used four different stages of
disease (I (mild), II (moderate), III (severe), and IV (very
severe)). The distribution of cases across these four stages (as
well as the prevalence of smoking among diagnosed cases) were
based on surveys undertaken in different parts of the world,
including the BOLD and PLATINO studies.16 17
Treatment strategies for COPD followed the GOLD guidelines,
which include the treatment of exacerbations as well as their
prevention through influenza vaccine and smoking cessation.15
For interventions focused on the management of exacerbations,
data on the average number and duration of exacerbations for
the different disease stages were used to determine eligibility
for treatment.18 Although coverage of these preventive and
management strategies in the two sub-regional populations
considered here is currently low, all interventions were assessed
at the relatively high coverage rate of 80% because of their
inherent feasibility (such as inhalers) or the severity of the
underlying condition (such as COPD stage III or IV).
Asthma
Interventions for the long term management of asthma, which
is based primarily on drug treatment, were selected on the basis
of recommendations in current clinical practice guidelines.19-22
Treatment aims to achieve and maintain control, since there is
good evidence that the clinical manifestations of the disease can
be controlled and progression of the disease can be altered with
appropriate treatment. This management approach uses
bronchodilators, long acting β agonists, corticosteroids, and
leukotriene receptor agonists. These treatment options are
organised by “steps” of increasing disease severity and treatment
intensity (doses and number of drugs), which are adjusted in a
continuous cycle: intermittent (step 1), mild (step 2), moderate
(step 3 or 4), and severe (step 5 or 6). In this stepwise approach,
which advises stepping down of treatment when control is
maintained for at least three months, interventions were
modelled to be given for a period of four months (subsequently
adjusted to a one year life cycle to conformwithWHO-CHOICE
standard cycle length).
The proportion of patients in each category was derived from
epidemiological cross sectional studies.23 24 As defined by the
Global Initiative for Asthma (GINA) guidelines,21 estimates of
the proportion of the total population targeted by interventions
were based on studies that reported how many patients
maintained total control at each treatment step.24-26 Since no such
reports were found for inhaled corticosteroids and leukotriene
receptor agonists, the relative risk of asthma exacerbations when
comparing inhaled corticosteroids with long acting β agonists
(relative risk 0.8327) was used as a proxy to determine the
proportion of patients maintaining control.
All interventions were assessed at a coverage level of 80%,
reflecting the wide availability of key drugs for asthma control
in low income resource settings (such as the β agonist
salbutamol; other drugs, however, such as beclometasone, are
less widely available).28
We did not include the treatment of acute asthma exacerbations
because of the endpoint definition used in the model (total
asthma control achievement, implying no exacerbations) and
the lack of information on both quality of life improvements in
under-controlled patients (including those presenting with
exacerbations) and the frequency of asthma exacerbations by
severity category.
Estimation and modelling of intervention
effectiveness
Disease progression and population health effects of
interventions were estimated using the multistate population
model PopMod (see general appendix on bmj.com). Regional
populations were categorised into two live health states—those
with the disease (state X, either asthma or COPD) and those
susceptible to but without the disease (state S)—and one state
where individuals are assumed to have died (dead state, D). We
did not take into account the comorbidity of asthma plus COPD,
which is a common clinical feature of chronic respiratory
diseases among elderly people. Starting from the healthy
(susceptible) state, individuals born into the population or
moving through its age span can either develop chronic
respiratory diseases or die, according to the estimated incidence
of chronic respiratory diseases and background mortality. The
model divides the population into males and females with age
groups of one year span (truncated at 100 years of age). The
health effects of implementing different interventions during a
10 year period are simulated over the maximum lifetime horizon
of the population, which is fixed at 100 years. Improvements
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in health due to intervention were compared with the disease
burden in the absence of all treatment. This counterfactual null
scenario was derived by back calculating the effect of
interventions at current levels of coverage. Accordingly,
intervention effectiveness is defined as the difference between
the disability adjusted life years (DALYs) averted under the
intervention versus the counterfactual scenario in which no
interventions take place. In accord with standard Global Burden
of Disease methodology, DALYs averted were age weighted
and discounted (at 3%).
Values for disease incidence, prevalence, case fatality, and
background mortality were obtained from the Global Burden
of Disease study estimates.1 29 Table 1⇓ summarises the main
epidemiological parameters used in the analysis. In regions
lacking accurate prevalence data based on spirometric screening,
disease occurrence was inferred from regional COPDmortality,
making use of the constraints imposed by the consistent
epidemiological relationships among prevalence, incidence,
remission, case fatality, and mortality.30 The relative risk of
COPDmortality across sub-regions was estimated as a function
of the two leading risk factors—tobacco smoking and indoor
air pollution from solid fuel used for cooking.9
In addition to mortality, the model also uses disability weights
to assess the morbidity component of DALYs. In line with
earlier Global Burden of Disease estimation,29 findings from
the Dutch disability weight study were used (on a scale 0–1,
where 0 denotes no disability).31 For COPD, disability weights
were 0.17 for mild or moderate COPD and 0.53 for severe
COPD. For asthma, the weights were 0.03 for intermittent and
mild persistent asthma, 0.23 for moderate persistent asthma,
and 0.36 for severe persistent asthma. We obtained a weighted
average for the disease state by multiplying the distribution of
cases by their respective disability weights.31-33
COPD is considered an irreversible condition,21 and we
accordingly set remission to zero; those who develop the disease
face an increased rate of mortality and disability, so treatment
effects were modelled through these two parameters (see table
2⇓). Given that no substantive report exists on the effect of
treatment on mortality from asthma, we evaluated the relative
effectiveness of interventions with respect to their effect on
morbidity, specifically by averting asthma associated disability
(taking control of asthma as the primary end point).
In order to estimate changes in disability weight, we used an
effect size approach. The effect size is a way of quantifying the
effectiveness of a particular intervention relative to some
comparison.34 35 It can bemeasured as the standardised difference
between two means. We used it to measure the difference
between the mean quality of life attained with the intervention
compared with placebo. Hedge’s correction formula was then
used to correct for sample bias in the studies selected as sources
for the effect size of interventions.
The effect size is then multiplied by a conversion factor to
translate this effectiveness into a reduction in disability weight.
The conversion factor provides the average change in disability
weight with one standard deviation difference in asthma
symptoms and functionality (that is, an effect size of 1). The
conversion factor for asthma was estimated from three studies
in which changes in symptoms, functionality, and use of
healthcare resources in response to various interventions were
measured in the same group of patients.33 The resulting
conversion factor of 0.13 was multiplied by the effect sizes of
interventions to reflect the reduction in disability weights (table
2⇓). In order to ensure consistency, we limited the criteria for
the literature search on the effectiveness of interventions to
randomised clinical trials that measured quality of life according
to the asthma quality of life questionnaire (AQLQ) and reported
means and standard deviations of mean differences of the
comparators.
Estimation and modelling of intervention
costs
Cost calculations used a standard ingredients approach with the
specification of quantities and unit prices of cost components.
Resource quantity estimates for a given level of effectiveness
were derived from published studies, where available, and
supplemented byWHO treatment guidelines and expert opinion.
For asthma treatment, primary care visits included costs for an
initial visit and two follow-up visits. These quantities followed
guidelines recommendations, in which the first follow-up visit
is scheduled a month after starting therapy to assess the benefits
of treatment and the second follow-up visit is scheduled at the
end of the fourth month of therapy, when full benefit of
treatment and disease control are assessed and it is decided
whether to step down treatment. Details for each intervention
are provided in the appendix on bmj.com.
COPD interventions considered in this study included patient
costs (those incurred at the point of delivery) and programme
costs (those associated with the development and administration
of the intervention and incurred at administrative levels outside
the point of delivery). In addition, the smoking cessation
intervention also included training costs to account for the
provision of group therapy sessions. Details of resource use for
each intervention are provided in the appendix on bmj.com.
Unit input prices were obtained from the WHO-CHOICE 2005
database. The price of traded goods was based on international
competitive prices (International Drug Price Indicator Guide
http://erc.msh.org) and the drug price lists from the governments
of New Zealand (www.pharmac.govt.nz) and Australia (www.
pbs.gov.au), plus a mark-up for transportation costs. The prices
of goods and services available locally (human resources, health
centre visits, etc) were based on cross country regressions
allowing for capacity adjustment.36 37 Costs for the 10 year
implementation period were discounted at 3% and expressed in
international dollars ($Int), which adjust for differences in the
relative price and purchasing power of countries and thereby
facilitate comparison across regions (that is, $Int1 buys the same
quantity of healthcare resources in Kenya or India as it does in
the United States). For the African and Asian sub-regions used
in this analysis, $Int1 is worth US$0.44 and US$0.32,
respectively.
Uncertainty analysis
Estimating cost effectiveness is inherently uncertain. For
instance, the effect size of interventions as observed in clinical
trials does not necessarily represent the effect size when the
same treatment is implemented in daily patient care. To address
this, we plot results on a double logarithmic scale, so as to
ascertain order of magnitude differences (such as $Int10–100
v $Int100–1000 per DALY averted). Second, we classify results
according to defined cost effectiveness thresholds:
WHO-CHOICE considers an intervention yielding a healthy
year of life for less than three times gross domestic product
(GDP) per capita as “cost effective” and an intervention yielding
a healthy year of life for less than one times GDP per capita as
“very cost effective.” In the sub-regions considered here, an
intervention yielding a DALY for <$Int2000 is considered
highly cost effective. Interventions yielding a DALY at a cost
greater than three times GDP per capita (that is, >$Int6000) are
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2012;344:e608 doi: 10.1136/bmj.e608 (Published 2 March 2012) Page 3 of 12
RESEARCH
 o
n
 7 M
ay 2020 at BVA. Protected by copyright.
http://www.bmj.com/
BM
J: first published as 10.1136/bmj.e608 on 2 March 2012. Downloaded from 
considered “not cost effective,” whereas those with a cost
effectiveness ratio falling between $Int2000 and $Int6000 are
considered “cost effective” in these sub-regions.25. Finally, for
the subset of interventions that are not dominated and therefore
fall on the cost effectiveness frontier, we undertook a
probabilistic uncertainty analysis using Monte Carlo methods
to assess the robustness of the results to potential changes in
key assumptions regarding the model parameters. We also
assessed the impact of removing age weights or discounting on
baseline results via one way sensitivity analysis.
Results
Table 3⇓ shows the main results of the analysis, including
DALYs averted, costs, average cost effectiveness ratio, and
incremental cost effectiveness for all interventions in both the
sub-Saharan African sub-region (Afr-E) and south east Asian
sub-region (Sear-D). To allow greater comparability with
interventions in other disease areas, we standardised both cost
and effectiveness estimates in relation to regional population
size. Effectiveness results are expressed in the number of
DALYs averted per million population per year of
implementation of the intervention. Cost results are expressed
in millions of international dollars per million population per
year, which is equivalent to the cost per capita.
Population level effect of interventions
The magnitude of impact of each intervention is different
between the two regions. For example, in the sub-Saharan
African sub-region all asthma interventions are noticeably more
cost effective than all COPD interventions. The case is
somewhat different in the South East Asian sub-region, where
one COPD intervention (flu vaccine) is competitive with asthma
interventions because of the higher underlying burden of COPD
in that region. However, the relative order of effectiveness
between regions is similar: inhaled bronchodilator (for COPD
stage II) is the most effective intervention in both regions,
averting 58 DALYs per million population per year of
intervention in Afr-E and 370 DALYs in Sear-D; the next most
effective in the Afr-E is low dose inhaled corticosteroids plus
long acting β agonists for moderate persistent asthma cases,
averting 45 DALYs, whereas in Sear-D the next is inhaled
bronchodilator and corticosteroid (for COPD stage III and IV),
which averts 151 DALYs (equivalent to 41%–76% of the
inhaled bronchodilator (COPD stage II) intervention).
Influenza vaccine in the sub-Saharan African sub-region and
medium dose inhaled corticosteroids for moderate persistent
asthma cases in the South East Asian sub-region are least
effective of the interventions analysed, producing only about
1%–7% of the number of DALYs averted by the use of inhaled
bronchodilator (COPD stage II) in both regions. Part of the
explanation for this relatively small impact is that flu vaccine
is expected to have no impact on COPD associated disability,
whereas use of long term anticholinergic bronchodilator is
expected to reduce COPD associated disability by up to 97%,
as measured by St George’s Respiratory. Questionnaire.38
Population level cost of interventions
The annual costs of interventions per million population ranged
from $Int49 000 to $Int749 000 in the sub-Saharan African
sub-region and from $Int12 000 to $Int4 225 000 in the South
East Asian sub-region (rounded to the nearest thousand). Cost
estimates of most interventions were appreciably different across
the two regions (table 3⇓). In general, asthma interventions in
the African sub-region were more costly than in the South East
Asian sub-region because of the larger number of patients
treated. The reverse was true with respect to COPD
interventions—that is, COPD interventions reported higher costs
in Sear-D than in Afr-E because of the high number of patients
who could benefit from treatment in that region. The
interventions inhaled bronchodilator (for COPD stage II),
inhaled bronchodilator and corticosteroid (COPD stage III and
IV), and oxygen therapy (COPD stage IV), which are based on
the administration of drugs, cost five times less in the
sub-Saharan African sub-region than in the south east Asian
sub-region. The cost per capita per year of influenza vaccine
was about the same in both regions.
There is substantial variation of population level cost of
interventions, ranging from a few cents per capita for low dose
inhaled corticosteroids given to patients as step 2 asthma
treatment to more than $Int4 per capita for inhaled
bronchodilator (for COPD stage II and III) in the South East
Asian sub-region.
In terms of cost breakdown, patient level costs are the main cost
component for most COPD interventions in both regions,
reflecting the high cost of drugs. The treatment of severe COPD
exacerbations also had a considerable cost (about 62%) resulting
from the provision of hospital bed days. For the provision of
oxygen therapy, inhaled bronchodilators, and corticosteroids,
patient level costs can account for more than 90% of total costs.
For asthma interventions with more than one drug—namely
inhaled corticosteroids plus long acting β agonists and inhaled
corticosteroids plus leukotriene receptor agonists—primary care
visits accounted for 24% of the total cost of these interventions,
while the drugs accounted for the remaining 76% of costs. For
the other interventions (low and medium dose inhaled
corticosteroids), these proportions were inverted, with primary
care visits and drugs accounting for 76% and 24% of costs,
respectively.
Cost effectiveness of interventions
The combined analysis of both costs and effects shows the
relative cost effectiveness of the interventions (figs 1⇓ and 2⇓).
The cost per DALY averted for all interventions analysed ranged
from $Int2686 to $Int39 307 in the sub-Saharan African region
and from $Int2420 to $Int50 651 in the South East Asian region.
In both regions, low dose inhaled corticosteroids for mild
persistent asthma was the most cost effective intervention,
costing an estimated $Int2420 (Sear-D) and $Int2686 (Afr-E)
per DALY averted. If more resources were to become available,
the incremental cost effectiveness ratio can be used to assess
each intervention in relation to the preceding most preferred
intervention. In the sub-Saharan African region, the next
preferred interventions on the basis of cost effectiveness were
low dose inhaled corticosteroids plus long acting β agonists for
moderate persistent asthma (incremental cost effectiveness ratio
$Int9112 per DALY averted) and next, inhaled bronchodilator
for COPD stage II ($Int36 769 per DALY averted). In the South
East Asian region, the next preferred interventions were
influenza vaccine for COPD ($Int4950 per DALY averted) and
inhaled bronchodilator for COPD stage II ($Int11 694 per DALY
averted).
The other interventions have considerably higher cost
effectiveness ratios (table 3⇓). For example, inhaled
bronchodilator and corticosteroid (COPD stages III and IV)
costs $Int13 000–14 000 per DALY averted, while treatment
of severe exacerbations costs around $Int18 000 per DALY
averted in sub-Saharan Africa and $Int9000 in South East Asia.
The cost effectiveness ratio of oxygen therapy is almost $Int40
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2012;344:e608 doi: 10.1136/bmj.e608 (Published 2 March 2012) Page 4 of 12
RESEARCH
 o
n
 7 M
ay 2020 at BVA. Protected by copyright.
http://www.bmj.com/
BM
J: first published as 10.1136/bmj.e608 on 2 March 2012. Downloaded from 
000 per DALY averted in sub-Saharan Africa region and in
excess of $Int50 000 per DALY averted in the South East Asian
region.
The results of this analysis suggest that, if funds are available,
both regions should first implement provision of low dose
inhaled corticosteroids for mild persistent asthma. Over 10 years,
this intervention would avert 100 239 DALYs at a cost around
$Int269m in the sub-Saharan African region and 67 000 DALYs
at a cost around $Int162m in South East Asian region.
Uncertainty analysis
The baseline effectiveness results in table 1⇓ allow for
discounting of health benefits at the rate of 3% per year and
also apply age specific weights, giving relatively more
importance to health gains in middle adult age as opposed to
younger and older ages. To examine the importance of these
sources of model uncertainty, the model was re-estimated first
without the age weights and then without both the age weights
and the discount factor. In both cases results were found to be
sensitive to the specification of the effectiveness measure.
Relaxing the age weighting assumption increased up to 64%
the number of DALYs averted (since health gains are in older
populations), while eliminating the rate of discount increased
benefits up to 113% (since health gains are not realised
immediately). As a consequence, cost effectiveness ratios were
reduced by up to 39% with the elimination of age weighting
and by up to 53% with the elimination of both age weighting
and discounting. Influenza vaccine and oxygen therapy were
relatively more affected among the interventions examined.
This implies that the baseline results should be interpreted as
conservative estimates of the cost effectiveness ratio.
A key parameter of the smoking cessation intervention was the
prevalence of smoking among people with diagnosed COPD.
As this information was not available for all regions, sensitivity
analysis was performed by halving the baseline scenario values
for this parameter in each region. Sensitivity analysis results
are similar in both regions. The total implementation cost is not
affected significantly, but the number of DALYs averted is
reduced by about 50% and the cost effectiveness ratio doubles
as the number of potential cases treated is reduced.
The probabilistic uncertainty analysis depicted in figures 3⇓
and 4⇓ shows the impact of plausible variations in total costs
and total effects and shows that the average cost effectiveness
ratio of most interventions would retain a classification of “cost
effective” or “not cost effective” after variation around the point
estimates was taken into account. A similar logic would apply
to the incremental cost effectiveness ratios. Concerning low
dose inhaled corticosteroids plus long acting β agonists for
moderate persistent asthma (intervention code AST-2) in the
South East Asian sub-region, however, figure 3⇓ shows that a
substantial part of the probability distribution for its average
cost effectiveness estimate would lie outside of the region
considered cost effective.
Discussion
Key findings and implications
Detailed analyses documenting the resource implications of
COPD and asthma interventions remain scarce, especially in
the area of hospital management, where the GOLD strategy was
unable to find any major contributions.15 This study set out to
produce uniform cost effectiveness estimates of several
interventions for COPD and asthma that can be used to inform
comparisons with investments in other disease areas and
treatment options. The results of the cost effectiveness analysis
reported here have implications for the allocation of resources
and priority setting across interventions in the wider group of
non-communicable diseases.
If resources are available, the results indicate that policy makers
in both regions should prioritise first the implementation of low
dose inhaled corticosteroids for mild persistent asthma. This
intervention is relatively inexpensive but averts a sizable number
of DALYs, avoiding exacerbations, which are an important
source of damage to quality of life and increased mortality.
Policy makers in the South East Asian region should also
consider the provision of influenza vaccine for COPD. In the
sub-Saharan African region policy makers should focus on the
provision of low dose inhaled corticosteroids plus long acting
β agonists for moderate persistent asthma as the next most cost
effective intervention. Medium dose inhaled corticosteroids for
moderate persistent asthma cases would make a further
important contribution to asthma control but is a less cost
effective option.
Comparedwith interventions to combat other chronic conditions,
COPD and asthma interventions seem to be of relatively poor
cost effectiveness. Two main factors seem to explain this
difference. Firstly, treatment interventions for chronic respiratory
diseases rely mostly on expensive imported drugs, as opposed
to interventions for other diseases, which that are often based
on less expensive local goods and services. Secondly, these
conditions are generally progressive, and COPD in particular
is irreversible and incurable, whichmeans that health gains from
combating chronic respiratory diseases would seem relatively
low compared with combating curable diseases.
There are further reasons for our conservative results for asthma.
Firstly, because of the inherent characteristics of the disease
and treatment, the impact of interventions was modelled for
four months (consistent with the treatment period of the stepwise
approach), and, for the remainder of the year, no treatment
effectiveness or improvement in asthma disability was assumed
(since treatment adjustment would be recommended, implying
different intervention scenarios). In reality, however, patients
would continue to be treated after their asthma had initially been
controlled, though with different treatment schemes (that may
or may not continue to control the asthma), but some would in
any case be experiencing improvements in quality of life. We
have not captured these changes in quality of life because of
the complexity in the definition of intervention scenarios and
the variability in patient profiles and clinical patterns. However,
although this component of asthma burden reduction has not
been captured in this analysis, we believe our results offer a
robust estimate of the benefits and costs of interventions as they
have been defined and are an accurate reflection of the
relationships among interventions.
On the other hand, the definition of asthma end point used was
stringent. In this analysis the proportion of patients that accessed
the interventions was obtained from the percentage of patients
achieving total control in randomised clinical trials. The
definition of total control derived from the clinical trials selected
for this study is more rigorous than that adopted by the
guidelines.19-21Consequently, the proportion of patients achieving
mere asthma control as per guidelines management goals would
be larger in real practice. This would increase the treated
populations and thus, the overall effectiveness of interventions.
However, the best information available on achieving asthma
control during the study conduction was that from clinical trials.
Related to the above, even if asthma control is not achieved,
improvements in quality of life can still be obtained with
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appropriate treatment.26 Therefore, treated patients with partly
controlled asthma, and even uncontrolled asthma, could
contribute to lessen asthma associated disability. Nevertheless,
we did not allow for improvements in asthma associated
disability for groups other than patients with fully controlled
asthma in order to conform with the guidelines’ definition of
asthma control, which is the current clinical standard. Lack of
information was another reason for not including improvements
in quality of life among patients with undercontrolled asthma.
However it is important to note that improvements in quality
of life of could occur with partly controlled asthma, which would
contribute to the reduction in disease burden with asthma
interventions.
Other interventions for asthma that are effective were not
considered in this analysis. This study focused on the long term
management of asthma and COPD directed at suppressing or
reversing inflammation and treating bronchoconstriction,
exacerbations, and related symptoms. Treatment of acute asthma
exacerbations and asthma educational interventions, which have
been shown to reduce morbidity and mortality in both children
and adults, were outside the scope of this analysis. Likewise,
the study has not incorporated the impact of interventions on
comorbidities.
Effect of uncertainty on the interpretation of
the results
Cost effectiveness results are inherently imbued with
uncertainty, and changes in parameters could impact the relative
order of cost effectiveness. Moreover, decision makers will
usually want to take other factors into account as well as cost
effectiveness. For instance, although influenza vaccine for
COPD cases, inhaled bronchodilator and corticosteroid (for
COPD stages III and IV), and all the other asthma-specific
interventions are not within the set of health maximising
interventions in the sub-Saharan African sub-region, their cost
effectiveness estimates are close to those of the interventions
in the optimal set. The same applies to the treatment of severe
COPD exacerbations, smoking cessation for COPD, and all the
other asthma-specific interventions in the South East Asian
sub-region. All drug interventions for asthma analysed could
be cost effective in both regions. On the other hand, we can be
much more confident that oxygen therapy is highly unlikely to
be cost effective in either of the regions considered. In both
regions, the use of inhaled bronchodilator (for COPD stage II)
comes as a relatively cost effective intervention, mainly because
of its substantial impact in improving quality of life.
The considerable uncertainty mentioned above provides support
also for other interventions, such as smoking cessation and
influenza vaccine, which come close to acceptable cost
effectiveness threshold. Therefore, taking a long term view
would imply that preventive strategies should be emphasised
in order to prevent the already large disease burden of asthma
and COPD from growing. This conclusion is largely similar to
that of Chan-Yeung et al,39 who conclude that tobacco control
is of paramount importance in resource poor countries in Asia
and Africa and that efforts should be directed towards
controlling tobacco smoking to reduce the burden of chronic
respiratory diseases. In some cases, the implementation of
treatment guidelines is of limited feasibility because spirometers
can be found only in major medical centres. Preventive
intervention strategies for the two main COPD risk factors
(smoking and air pollution) are currently available that can be
shown very cost effective when compared with other strategies
focused on disease management and symptom relief. For
instance, Mehta and Shahpar12 calculate that reducing exposure
to indoor air pollution from solid fuel use by promoting the use
of improved stoves would cost $Int500 per DALY in the
sub-Saharan African sub-region Afr-E and $Int730 per DALY
in the South East Asian sub-region Sear-D.
As emphasised in our sensitivity analysis, considerable
uncertainty remains about key parameters related to the
epidemiology of COPD and its risk factors. More research is
needed to provide the necessary information, including the
contextualisation of this analysis to national settings. In
summary, this study has quantified the health effects and costs
of the most effective interventions for asthma and COPD
management and has identified the health maximising
interventions to reduce the risk of the disease in resource limited
settings. Scaling up these interventions could bring important
reductions in the burden of chronic respiratory diseases in the
two regions studied. Since drugs are the main component of
asthma and COPD management, access to treatment should be
a main concern in improving care and reducing the disease
burden in these regions.
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Tables
Table 1| Main epidemiological parameters used in analysis of asthma and chronic obstructive pulmonary disease (COPD) inWHOsub-Saharan
African sub-region AfrE and South East Asian sub-region SearD by sex and age
Age groups (years)
SexModel parameter ≥8070–7960–6945–5930–4415–295–140–4
African sub-region AfrE
Disease incidence (per 1000 population)
0.50.550.691.21.615.897.158.43MaleAsthma
1.191.231.470.880.363.526.235.48Female
9.785.434.621.430.180.090.070MaleCOPD
4.292.251.060.40.10.0100Female
Disease prevalence (per 1000 population)
25.828.93236.242.258.958.518.8MaleAsthma
42.844.34647.346.850.145.411.3Female
31.630.227.59.21.541.060.020MaleCOPD
7.857.966.72.610.30.0600Female
Disease mortality (per 1000 population)
0.070.040.020.0100.0200MaleAsthma
0.090.040.020.010000Female
11.45.42.670.580.08000MaleCOPD
4.682.130.880.200.03000Female
South East Asian sub-region SearD
Disease incidence (per 1000 population)
0.510.390.50.831.224.454.394.43MaleAsthma
0.830.840.920.540.371.843.653.02Female
10.99.08.32.10.54000MaleCOPD
9.246.854.322.270.33000Female
Disease prevalence (per 1000 population)
19.721.925.128.231.140.534.112.5MaleAsthma
27.528.329.630.629.230.127.28.40Female
25.64532.145.55.92000MaleCOPD
1719.720.840.43.45000Female
Disease mortality (per 1000 population)
0.010.0100.010000MaleAsthma
0.010.0100.010000Female
9.958.333.11.640.09000MaleCOPD
7.554.092.021.470.05000Female
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Table 2| Treatment effect size estimates and impact on disability weights for chronic obstructive pulmonary disease (COPD) and asthma
in WHO sub-Saharan African sub-region AfrE and South East Asian sub-region SearD
Change in value, and data source
Effect sizeIntervention MortalityDisability weights
COPD
−0.15410.01400.08Smoking cessation
−0.1243−0.0542−0.39Flu vaccine
0450.24441.83Bronchodilator (for COPD stage II)
−0.2547 480.16461.22Bronchodilator + corticosteroid (COPD stage III and IV)
−0.0649 51−0.0550−0.42Severe exacerbation treatment
−0.5053−0.1152−0.87Oxygen therapy
Asthma
N/A0.0124-260.05Placebo (asthma)
N/A0.124 250.76Low dose inhaled corticosteroids
N/A0.1224 260.95Medium dose inhaled corticosteroids
N/A0.1624 261.22Low dose inhaled corticosteroids + long acting β agonists
N/A0.1524 26 541.17Inhaled corticosteroids + leukotriene receptor agonists
N/A = Not applicable
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Table 3| Costs, effects, and cost-effectiveness of interventions to combat asthma and chronic obstructive pulmonary disease (COPD) in
WHO sub-Saharan African sub-region AfrE and South East Asian sub-region SearD
WHO Asian sub-region SearDWHO African sub-region AfrE
Intervention
Cost effectiveness ratio
Annual cost
per capita
($Int)
Annual
DALYs
saved per
million
population
Cost effectiveness ratio
Annual cost
per capita
($Int)
Annual
DALYs
saved per
million
population Incremental†Average*Incremental†Average*
Asthma
2420242011 70652686268666 98225AST-1: Low dose inhaled
corticosteroids (for mild persistent
asthma )
Dominated‡548246 886991125512245 34645AST-2: Low dose inhaled
corticosteroids + long acting β
agonists (moderate persistent
asthma)
Dominated‡459918 3244Dominated‡4995104 50121AST-3: Medium dose inhaled
corticosteroids (moderate
persistent asthma)
Dominated‡707551 1047Dominated‡6772256 84338AST-4: Low dose inhaled
corticosteroids + leukotriene
receptor agonists (moderate
persistent asthma)
COPD
Dominated‡11 9241 295 722109Dominated‡20 051391 79220COPD-1: Smoking cessation
4950401052 21713Dominated‡13 26148 6314COPD-2: Influenza vaccine
11 69411 4244 225 17437036 76912 868749 04758COPD-3: Inhaled bronchodilator
(COPD stage II)
Dominated‡14 2542 149 094151Dominated‡13 164420 80132COPD-4: Inhaled bronchodilator
+ corticosteroid (COPD stage III
and IV)
Dominated‡8826281 95632Dominated‡17 765117 3257COPD-5: Treatment of severe
exacerbations
Dominated‡50 6511 891 77637Dominated‡39 307376 52110COPD-6: Oxygen therapy + drugs
(COPD stage IV)
DALYs=disability adjusted life years. $Int=international dollars.
*$Int per DALY averted relative to no intervention.
†$Int per DALY averted, within intervention cluster
‡Intervention is more costly or less effective than other more efficient interventions, and results are therefore not included here.
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Figures
Fig 1 Cost effectiveness isoquants of interventions for chronic obstructive pulmonary disease (COPD) and asthma
interventions (at 80% coverage) for sub-Saharan African sub-region Afr-E. See table 3⇓ for explanation of intervention
codes
Fig 2 Cost effectivenes isoquants of chronic obstructive pulmonary disease (COPD) and asthma interventions (at 80%
coverage) for South East Asian sub-region Sear-D. See table 3⇓ for explanation of intervention codes
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Fig 3 Probabilistic uncertainty graph of interventions for chronic obstructive pulmonary disease (COPD) and asthma
interventions (at 80% coverage) for sub-Saharan African sub-region Afr-E. See table 3⇓ for explanation of intervention
codes
Fig 4 Probabilistic uncertainty graph of interventions for chronic obstructive pulmonary disease (COPD) and asthma
interventions (at 80% coverage) for WHO South East Asia sub-region SearD. See table 3⇓ for explanation of intervention
codes
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